 SAN FRANCISCO, Sept. 30, 2021 GLOBE NEWSWIRE -- Olema Pharmaceuticals, Inc. Olema or Olema Oncology, Nasdaq: OLMA, a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for womens cancers, today announced a poster presentation on OP-1250, a complete estrogen receptor ER antagonist CERAN and a selective ER degrader SERD being developed for the treatment of metastatic breast cancer and other womens cancers, at the upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, being held virtually from October 7-10, 2021. 